← ANALYST RATINGS · TIPRANKS
Vor Biopharma (VOR): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $37.67, the highest $50.00, the lowest $27.00. The average is +108.9% from the last price of $18.03.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $50.00 | Buy | +177.3% | Reiterated | 15.10.26on TipRanks 07:55 | +2.9%next day −5.7% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $40.00 | Buy | +121.9% | Reiterated | 28.09.26on TipRanks 06:55 | −0.4%next day +0.3% · 5 days +0.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $24.50 → $19.00−22.4% | Hold | +5.4% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $24.50 → $18.50−24.5% | Hold | +2.6% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $23.50 → $18.50−21.3% | Hold | +2.6% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.50 → $19.00−19.1% | Hold | +5.4% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.50 → $18.50−21.3% | Hold | +2.6% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.50 → $19.00−19.1% | Hold | +5.4% | Reiterated | 24.09.26on TipRanks 12:05 | — | |
| Farzin Haque★★★★★★★★★★#6078 · hits 55% · avg +7.3% | Jefferies | $48.00 | Buy | +166.2% | Reiterated | 09.09.26on TipRanks 09:55 | −7.0%next day −3.3% · 5 days −4.4% | ↗ |
| Sadia Rahman★★★★★★★★★★#5292 · hits 70% · avg +11.8% | Wells Fargo | $30.00 | Buy | +66.4% | Reiterated | 31.08.26on TipRanks 09:50 | −0.5%next day +1.4% · 5 days +11.8% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $18.00 → $27.00+50.0% | Hold | +49.8% | Reiterated | 12.08.26on TipRanks 09:56 | −5.5%next day +3.6% · 5 days +6.0% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $31.00 | Buy | +71.9% | Reiterated | 12.08.26on TipRanks 06:30 | −5.5%next day +3.6% · 5 days +6.0% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | — | Buy | — | Reiterated | 13.05.26on TipRanks 14:25 | −4.0%next day −6.1% · 5 days −2.1% | ↗ |
| Jack Allen★★★★★★★★★★#12322 · hits 30% · avg −16.3% | Robert W. Baird | $64.00 → $46.00−28.1% | Buy | +155.1% | Reiterated | 23.12.25on TipRanks 07:05 | −1.8%next day +7.0% · 5 days −2.4% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $43.00 → $40.00−7.0% | Buy | +121.9% | Reiterated | 18.12.25on TipRanks Dec 19 07:10 | −11.0%next day −4.0% · 5 days +12.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Vor Biopharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $37.67 at a price of $19.08 (+97.4%); now: $37.67 at $18.03 (+108.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 5 | 2 | 1 | 4 | 5 |
| Buy | 2 | 1 | 1 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.85 (from $-1.09 to $-0.72). Last quarter: $-1.16.
Best top-analyst consensus in the sector · Healthcare
About Vor Biopharma
- CEO: Jean-Paul Kress
- Employees: 76
- 500 Boylston Street, Boston, MA, 02116, US
- www.vorbio.com
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 84 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗